Clinical Trials Logo

EBV-induced Lymphomas clinical trials

View clinical trials related to EBV-induced Lymphomas.

Filter by:
  • None
  • Page 1

NCT ID: NCT01498484 Completed - Clinical trials for EBV-associated Malignancies

Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies

Start date: December 2011
Phase: Phase 2
Study type: Interventional

This is a Phase II trial to evaluate the efficacy and safety of human leukocyte antigen (HLA) partially-matched third-party allogeneic Epstein-Barr virus cytotoxic T lymphocytes (EBV-CTLs) for the treatment of EBV-induced lymphomas and EBV-associated malignancies.

NCT ID: NCT00002663 Completed - Clinical trials for EBV-associated Malignancies

Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

Start date: March 1995
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.